unknown
Stage
About
Inossia develops a softener for bone cements used in vertebral augmentation procedures to better match the mechanical properties of osteoporotic bone and reduce the risk of new spinal fractures. The company is running a randomized multicenter clinical trial across 9 hospitals in Spain, Poland, Germany and Canada (196 participants) and has pursued regulatory pathways including a US FDA Breakthrough Device designation.
Explore Inossia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.